Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) plays an important role in the treatment of non-small cell lung cancer. However,after EGFR-TKI therapy for six to twelve months, acquired resistance may occur in patients who are initially sensitive to it, which blocks the sustained medication. This article mainly reviews the mechanism of acquired resistance of non-small cell lung cancer to EGFR-TKI including T790M mutation and MET amplification and the progress on new generation tyrosine kinase inhibitor and other targeted agents. Key words: Non-small cell lung cancer; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired resistance; T790M mutation; MET amplification
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
